10x Genomics (TXG) +35.7% in 30 Days: What Powered the Move
Key Takeaways
- 10x Genomics (TXG) shares climbed roughly 35.7% over the trailing 30 days, rising from a closing price of $47.05 to about $63.87.
- The advance was powered by a stronger-than-expected Q2 2026 report, an upward revision to full-year revenue guidance, and early enthusiasm for the new Atera spatial biology platform.
- Management raised its 2026 revenue outlook to $610–$630 million and pointed to AI-driven demand for biological data as a structural tailwind.
- The broader quarter reflects a multi-month re-rating built on product innovation, the Proteintech Genomics acquisition, and high-profile research collaborations.
Company Overview and Market Position
10x Genomics designs and sells instruments, consumables, and software for analyzing biological systems at single-cell and spatial resolution. Its main platforms—Chromium for single-cell work and the Visium and Xenium spatial products—allow researchers to measure gene expression, epigenetics, and protein activity in large experiments. The company serves academic institutions, academic medical centers, and biopharmaceutical firms in the expanding single-cell and spatial biology segment. I keep an eye on TXG because of its recurring consumables revenue, leadership in high-resolution analysis, and exposure to AI applications in drug discovery and research. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance Over the Last 30 Days and Quarter
Over the last 30 days, TXG moved from a closing price of $47.05 on July 22, 2026, to roughly $63.87, a gain of about $16.82 or approximately 35.7%. This marked a clear breakout after the stock had traded in the mid-to-high $40s for much of July. The quarterly view looks even stronger: as of early August, TXG had risen more than 110% over the trailing three months, extending a recovery from its 52-week low of $11.16. The multi-month uptrend points to improving demand fundamentals and a shift in sentiment toward life-science tools.
What Drove the Stock in the Last 30 Days
The main catalyst arrived in early August with second-quarter 2026 results that beat expectations. Revenue reached $151 million against a consensus estimate near $146.5 million, while the adjusted loss of $0.14 per share came in narrower than the roughly $0.24 loss analysts had projected. On a reported basis, revenue fell about 12.6% year over year, but excluding non-recurring settlement revenue it rose 3%. Management raised full-year 2026 revenue guidance to $610 million–$630 million from the prior $600 million–$625 million range. The higher outlook reflected strong early demand for Atera, the next-generation spatial whole-transcriptome platform. Booked Atera orders by quarter-end already exceeded the roughly 40 systems expected to ship in 2026, with manufacturing capacity rather than demand limiting shipments. The period also included the Proteintech Genomics acquisition, which expanded proteomics and multi-omics capabilities, plus a strategic research collaboration with the Cleveland Clinic. Gross margin improved to 74%, cash and marketable securities rose to about $552 million, and the company ended the quarter with no debt. These elements, along with growing attention on AI-driven biological research, supported the rally.
What Drove Performance Over the Last Quarter
The quarterly advance reflects a broader narrative shift. The Atera launch earlier in the year, unveiled at the AACR Annual Meeting 2026, positioned the company to expand its spatial biology opportunity and total addressable market. Early commitments from global service providers and AI-focused research programs added confidence in the platform’s potential. Underlying momentum includes improving academic funding dynamics after several challenging years, plus rising demand for high-quality single-cell and spatial data to train AI models. The Proteintech Genomics acquisition and Cleveland Clinic collaboration further broadened multi-omics and translational research reach, while the beat-and-raise report provided fresh evidence of improving fundamentals.
What to Watch Next for TXG
Several factors should shape the trajectory in coming quarters. The pace of Atera instrument shipments, heavily weighted toward the fourth quarter, will remain a focus, as will consumables pull-through once systems are installed. Management has signaled a modest sequential revenue decline in the third quarter as customers defer purchases of existing Xenium and Visium products ahead of the Atera transition. I’m watching the academic funding environment closely, along with competitive developments in spatial and single-cell biology. AI-related demand for large-scale biological datasets, adoption of the Flex Apex assay, and integration of Proteintech Genomics’ protein-analysis capabilities represent additional potential catalysts. Persistent operating losses and execution risk around manufacturing ramp-up remain the main considerations.
Using Tickeron’s Trending AI Robots
For traders looking for a systematic way to track momentum across thousands of equities, I often turn to Tickeron’s Trending AI Robots page. It provides a curated view of AI-driven trading bots that monitor thousands of tickers, featuring only the top-performing and most relevant ones. These bots cover different strategies, timeframes, and performance metrics, helping align tools with individual research and trading approaches.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
TXG in downward trend: price may drop because broke its higher Bollinger Band on September 17, 2026
TXG broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 35 similar instances where the stock broke above the upper band. In 32 of the 35 cases the stock fell afterwards. This puts the odds of success at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 08, 2026. You may want to consider a long position or call options on TXG as a result. In 66 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for TXG just turned positive on September 14, 2026. Looking at past instances where TXG's MACD turned positive, the stock continued to rise in 35 of 45 cases over the following month. The odds of a continued upward trend are 78%.
Following a +8.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where TXG advanced for three days, in 207 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 190 of 235 cases where TXG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TXG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.092) is normal, around the industry mean (10.643). P/E Ratio (0.000) is within average values for comparable stocks, (100.549). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.062). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (15.038) is also within normal values, averaging (39.536).
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TXG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a life science technology company, which engages in building products to interrogate, understand and master biology
Industry MedicalNursingServices
Advertisement